MesoTV | Discussion about NIH natural history study of patients with malignant mesothelioma with Raffit Hassan
Read More
JUST PUBLISHED: Results of combination standard chemotherapy with immunotherapy study in mesothelioma show improved survival and response rate
Read More
Released 3-year survival data for nivolumab/ipilimumab combination immunotherapy for mesothelioma
Read More
Clinical trial combining chemotherapy with immunotherapy now open in the United States
Read More
Nivolumab trial results make it a promising treatment for relapsed (previously treated) mesothelioma patients
Read More
MesoTV: Overview of enrolling CAR-T cell therapy trial targeting mesothelin
Read More